Olga Ovcinnikova

Olga Ovcinnikova

Auto-generated profile, based on publicly available information

Olga Ovcinnikova

MSD Limited, London, England, UK

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2024 in Journal of Medical Economics
Verified
Journal Article
Open access
GBGoran Bencina
Goran Bencina
USUgne Sabale
Ugne Sabale
EMEdith Morais
Edith Morais
OOOlga Ovcinnikova
Olga Ovcinnikova
EOEdward Oliver
Edward Oliver
KSKarin Sundström
Karin Sundström
The economic and mortality burden of cancer is high worldwide. In Europe, cancer was responsible for 1.3 million deaths in 2020 and incurred an estimated cost of €50 billion from premature mortality. Human papillomavirus (HPV) and hepatitis B virus (HBV) are among the leading causes of infection-related cancers despite the availability of effective vaccines against these infections. This analysis estimated the mortality and productivity loss of HBV- and HPV-associated cancers that could be preventable through vaccination across European regions. Institute for Health Metrics Evaluation (IHME) data were used to estimate mortality, years of life lost (YLL), and the value of years of life lost (VYLL) from five HBV- and HPV-related cancers (oral cavity, oropharynx, larynx, cervical, and liver cancers) across 40 European countries in 2019. Preventable deaths and YLL were estimated based on fractions attributable to infections. Data from the World Bank on GDP per capita were used to estimate the VYLL. The robustness of these results was explored with sensitivity and scenario analyses. In 2019, 31,906 cancer deaths resulted in an economic burden of €18,521,614,725 due to productivity losses across Europe. HPV-related cervical cancer had the highest mortality (19,473 deaths) and economic burden (€10,706,253,185). HBV-related liver cancer and HPV-related larynx, oral cavity, and oropharynx cancers also had a substantial burden, particularly in males. Eastern Europe had the highest YLL (308,179; 39%) and Western Europe was responsible for the greatest VYLL (€8,281,306,504; 45%), although the highest VYLL per death was in Northern Europe (€923,638). HPV-related oropharynx cancer had the highest VYLL per death (€656,607). HPV- and HBV-related cancer deaths are associated with substantial mortality and productivity losses in Europe, which could be reduced by the continued prioritization and implementation of prophylactic public health measures including systematic awareness, vaccination, and screening efforts.

1 December 2021 in Future Oncology
Verified
Journal Article
Open access
AAAjibade O Ashaye
Ajibade O Ashaye
HBHeather Burnett
Heather Burnett
SASeye Abogunrin
Seye Abogunrin
HPHemangi Panchmatia
Hemangi Panchmatia
OOOlga Ovcinnikova
Olga Ovcinnikova
MDMehul Dalal
Mehul Dalal
Aim: To understand the burden of treatment-naive peripheral T-cell lymphoma (PTCL). Methods: A systematic literature review was conducted in November 2020 following best practice methodology. Resul... Lay abstract Peripheral T-cell lymphoma (PTCL) is an aggressive cancer that develops from white blood cells called T cells, which are an important part of the immune system. There is limited knowle...

1 January 2026 in BMJ Public Health
Verified
Journal Article
Open access
PDF file
CPCody Palmer
Cody Palmer
OOOlga Ovcinnikova-Hutchings
Olga Ovcinnikova-Hutchings
KEKayla Engelbrecht
Kayla Engelbrecht
GFGiampiero Favato
Giampiero Favato
ASAlexandra Stewart
Alexandra Stewart
VDVincent Daniels
Vincent Daniels
Introduction: National Health Service (NHS) England has committed to eliminating cervical cancer as a public health problem by 2040, defined as an incidence of below 4 per 100 000 woman-years. This study aims to estimate the contributions of currently available interventions to cervical cancer elimination and assess how improvements in human papillomavirus (HPV) vaccination coverage, cervical cancer screening and treatment following an abnormal screen would impact the timeline for achieving this elimination target. Methods: Using a previously published mathematical model that captured historical changes in HPV vaccination and screening programmes in England, cervical cancer incidence was forecasted from 2024 through 2124. Various scenarios were explored to assess the impact of resolving issues in disparities of screening coverage, low adherence to follow-up of abnormal screens and increasing vaccination coverage over time. Consistent with other cervical cancer elimination models in high-income countries, we also considered a more ambitious cervical cancer incidence threshold of below 1 per 100 000 woman-years. Results: With current screening and vaccination levels, it was estimated that England could achieve cervical cancer elimination (incidence of below 4 per 100 000) by approximately 2050. Achieving this target by 2040 would necessitate improved follow-up of abnormal screens and increased cervical cancer screening uptake in under-screened populations. The aspirational threshold can only ever be achieved with both improved screening (in follow-up and coverage disparities) and high vaccination rates. These results are consistent with other UK-specific model results. Conclusions: Improvements in follow-up of abnormal screens and decreasing disparities in screening coverage will be necessary if England is to attain the 2040 elimination goal. Meanwhile, consistent high vaccination coverage will ensure future population protection and enable more aspirational thresholds to be achieved.